A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

Trial Profile

A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs LMB 100 (Primary) ; SEL-403 (Primary) ; Sirolimus (Primary)
  • Indications Mesothelioma
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Mar 2018 Planned number of patients changed from 40 to 20.
    • 12 Mar 2018 According to a Selecta Biosciences media release, first patient has been dosed in this trial.
    • 03 Mar 2018 Planned initiation date changed from 8 Mar 2018 to 9 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top